{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:57Z","timestamp":1787071077014,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Breast carcinoma diagnosis can be made with core-needle biopsy (CNB), but there are controversies regarding the evaluation of hormone receptor (HR) status in needle biopsy specimens. When preoperative neoadjuvant therapy is required in breast cancer cases, the CNB specimen should be evaluated to decide on the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>\n                      In this study, we aimed to compare the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and silver\n                      <jats:italic toggle=\"yes\">in situ<\/jats:italic>\n                      hybridization (SISH) results of the CNB specimens and surgical specimens (SS) of our breast carcinoma cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This retrospective study included cases diagnosed with breast cancer in our center for approximately 1 year between 2017 and 2018. About 97 cases with both CNB specimens and SS were included in the study. Data such as the ER, PR, HER2, and SISH evaluation results in CNB and SS, age distribution and histopathological type, metastatic lymph nodes, lymphovascular invasion, tumor size, and grade of the tumor were recorded. The data were analyzed using SPSS 22.0 (Statistical Package for the Social Sciences, Armonk, NY, USA) software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      All of the cases were female and 70.1% of them were aged over 45. About 27.8% of the cases were aged 31\u201345 years, and 2.1% were aged under 30. When evaluated according to the histopathological type of the tumor, 71.1% of cases were invasive ductal carcinoma (IDC), 8.2% were invasive lobular carcinoma (ILC), 6.2% were IDC + ILC, 11.3% were another carcinoma, and 3.1% were\n                      <jats:italic toggle=\"yes\">in situ<\/jats:italic>\n                      carcinoma. 12.4% of the cases were Grade I, 43.3% were Grade II, and 20.6% were Grade III. 43.3% of our cases' tumor size were \u22642 cm and 56.7% &gt;2 cm. 50 (51.5%) of these cases had no lymph node metastasis. It was found out that 36 (37.1%) of the cases had 1\u20134 metastatic lymph nodes and 11 (11.3%) of them had 5 and more metastatic lymph nodes. It was found out that 44 (45.4.%) of the cases had no lymphovascular invasion and 53 (54.6%) of them had a lymphovascular invasion. When HR statuses in CNB and SS were compared, ER was found to have a sensitivity of 96.1% and a specificity of 100%. PR was found to have a sensitivity of 94.2% and a specificity of 66.7%. HER2 was found to have a sensitivity of 100% and a specificity of 73.4%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>ER evaluation results are reliable in deciding on needle biopsy material. PR may show the heterogeneous distribution in HER2 tumor. Thus, if PR and HER2 results in needle biopsy material are negative, assessments should be repeated in SS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_601_20","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:37:21Z","timestamp":1668645441000},"page":"1789-1795","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["A single centre experience in Turkey for comparison between core needle biopsy and surgical specimen evaluation results for HER2, SISH, estrogen receptors and progesterone receptors in breast cancer patients"],"prefix":"10.4103","volume":"18","author":[{"given":"Hatice","family":"Karaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Senel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Tasdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipek","family":"\u00d6zer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-52-20241021","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/1097-0142(19930315)71:6+<2127::AID-CNCR2820711602>3.0.CO;2-2","article-title":"Risk factors for breast cancer","volume":"71","author":"Henderson","year":"1993","journal-title":"Cancer"},{"key":"R2-52-20241021","first-page":"791","article-title":"Breastfeeding reduces breast cancer risk: A case-control study in north India","volume":"5","author":"Kumar","year":"2014","journal-title":"Int J Prev Med"},{"key":"R3-52-20241021","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1056\/NEJMra012284","article-title":"Breast and ovarian cancer","volume":"348","author":"Wooster","year":"2003","journal-title":"N Engl J Med"},{"key":"R4-52-20241021","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.amjsurg.2010.02.015","article-title":"A comparative analysis of core needle biopsy and final excision for breast cancer: Histology and marker expression","volume":"201","author":"Ough","year":"2011","journal-title":"Am J Surg"},{"key":"R5-52-20241021","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4103\/0971-5851.125237","article-title":"Needle core biopsy for breast lesions: An audit of 467 needle core biopsies","volume":"34","author":"Radhakrishna","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"R6-52-20241021","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1038\/modpathol.2010.55","article-title":"Issues and updates: Evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer","volume":"23","author":"Allred","year":"2010","journal-title":"Mod Pathol"},{"key":"R7-52-20241021","doi-asserted-by":"crossref","first-page":"515","DOI":"10.5812\/ircmj.10232","article-title":"Accuracy of estrogen and progesterone receptor assessment in core needle biopsy specimens of breast cancer","volume":"15","author":"Omranipour","year":"2013","journal-title":"Iran Red Crescent Med J"},{"key":"R8-52-20241021","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2559.1989.tb01623.x","article-title":"Oestrogen receptors in benign epithelial lesions and intraductal carcinomas of the breast: An immunohistological study","volume":"15","author":"Giri","year":"1989","journal-title":"Histopathology"},{"key":"R9-52-20241021","first-page":"827","article-title":"Evaluation of HER-2\/neu (erbB-2) status in breast cancer: From bench to bedside","volume":"12","author":"Hanna","year":"1999","journal-title":"Mod Pathol"},{"key":"R10-52-20241021","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"key":"R11-52-20241021","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/annonc\/mdx397","article-title":"Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer","volume":"28","author":"Fujii","year":"2017","journal-title":"Ann Oncol"},{"key":"R12-52-20241021","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"R13-52-20241021","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/path.2808","article-title":"The molecular pathology of breastcancer progression","volume":"223","author":"Bombonati","year":"2011","journal-title":"J Pathol"},{"key":"R15-52-20241021","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2559.1992.tb01032.x","article-title":"Pathological prognostics factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up","volume":"20","author":"Ellis","year":"1992","journal-title":"Histopathology"},{"key":"R16-52-20241021","doi-asserted-by":"crossref","first-page":"238","DOI":"10.7326\/0003-4819-152-1-201001050-00190","article-title":"Systematic review: Comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions","volume":"152","author":"Bruening","year":"2010","journal-title":"Ann Intern Med"},{"key":"R17-52-20241021","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s10549-012-1990-z","article-title":"Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: A meta-analysis","volume":"134","author":"Chen","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"R18-52-20241021","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0039-128X(03)00122-3","article-title":"Steroid receptors and proliferation in the human breast","volume":"68","author":"Clarke","year":"2003","journal-title":"Steroids"},{"key":"R19-52-20241021","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/1097-0142(19911101)68:9<1918::AID-CNCR2820680913>3.0.CO;2-L","article-title":"Reappraisal of internal mammary node metastases as a prognostic factor in patients with breast cancer","volume":"68","author":"Noguchi","year":"1991","journal-title":"Cancer"},{"key":"R21-52-20241021","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/bcr452","article-title":"The role of estrogen and progesterone receptors in human mammary development and tumorigenesis","volume":"4","author":"Anderson","year":"2002","journal-title":"Breast Cancer Res"},{"key":"R22-52-20241021","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/modpathol.3800229","article-title":"Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study","volume":"17","author":"Mohsin","year":"2004","journal-title":"Mod Pathol"},{"key":"R23-52-20241021","first-page":"133","article-title":"Predicting endocrine therapy responsiveness in breast cancer","volume":"23","author":"Ma","year":"2009","journal-title":"Oncology (Williston Park"},{"key":"R25-52-20241021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10911-009-9116-x","article-title":"Stemming resistance to HER-2 targeted therapy","volume":"14","author":"Bedard","year":"2009","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"R26-52-20241021","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3322\/canjclin.47.1.28","article-title":"Tumor-related prognostic factors for breast cancer","volume":"47","author":"Donegan","year":"1997","journal-title":"CA Cancer J Clin"},{"key":"R27-52-20241021","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3816\/CBC.2010.n.021","article-title":"Breast cancer hormone receptor assay results of core needle biopsy and modified radical mastectomy specimens from the same patients","volume":"10","author":"Uy","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"R28-52-20241021","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"R29-52-20241021","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/jcp.50.1.27","article-title":"Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma","volume":"50","author":"Zidan","year":"1997","journal-title":"J Clin Pathol"},{"key":"R30-52-20241021","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdp234","article-title":"Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)","volume":"20","author":"Arnedos","year":"2009","journal-title":"Ann Oncol"},{"key":"R31-52-20241021","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ejso.2016.10.025","article-title":"Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature","volume":"43","author":"Meattini","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"R32-52-20241021","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/bcr3658","article-title":"Breast cancer intra-tumor heterogeneity","volume":"16","author":"Martelotto","year":"2014","journal-title":"Breast Cancer Res"},{"key":"R33-52-20241021","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jamcollsurg.2012.09.007","article-title":"Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?","volume":"216","author":"Greer","year":"2013","journal-title":"J Am Coll Surg"},{"key":"R34-52-20241021","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"R35-52-20241021","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1245\/s10434-019-07480-y","article-title":"Clinicopathological features and disease outcome in breast cancer patients with hormonal receptor discordance between core needle biopsy and following surgical sample","volume":"26","author":"Zhu","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"R36-52-20241021","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4132\/jptm.2019.10.14","article-title":"Analysis of the molecular subtypes of preoperative core needle biopsy and surgical specimens in invasive breast cancer","volume":"54","author":"Jeong","year":"2020","journal-title":"J Pathol Transl Med"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_601_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:41:07Z","timestamp":1787067667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_601_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_601_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}